Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 78430-91-8 | MDL No. : | MFCD28346936 |
Formula : | C12H12N2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | RURRSGMFTZVXKB-UHFFFAOYSA-N |
M.W : | 184.24 | Pubchem ID : | 18000062 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 11 |
Fraction Csp3 : | 0.08 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 58.07 |
TPSA : | 17.82 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | Yes |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.73 cm/s |
Log Po/w (iLOGP) : | 2.11 |
Log Po/w (XLOGP3) : | 2.38 |
Log Po/w (WLOGP) : | 2.47 |
Log Po/w (MLOGP) : | 1.85 |
Log Po/w (SILICOS-IT) : | 2.65 |
Consensus Log Po/w : | 2.29 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.87 |
Solubility : | 0.251 mg/ml ; 0.00136 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.4 |
Solubility : | 0.742 mg/ml ; 0.00403 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.78 |
Solubility : | 0.0307 mg/ml ; 0.000167 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.55 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71% | With sodium hydrogencarbonate In water; acetone at 20 - 50℃; for 20 h; | NaHCO3 (5.25 g, 62.40 mmol, 1.25 eq) was added to aceton/water (1:1 v:v, 160 mL) and this solution wasstirred 1 hour. To this mixture, imidazole (13.61 g, 199.00 mmol, 4 eq) was added and stirred until it wascompletely dissolved, then 1-(chloromethyl)-4-vinylbenzene (7.1 ml, 49.80 mmol, 1 eq) was added dropwiseat room temperature. After the addition, reaction mixture was heated to 50 oC and stirred for 20 h (monitoredby TLC). Acetone was removed in vacuo, and remaining solution was extracted with diethyl ether. 2 M HClwas added to the organic phase until pH = 4-5, and it was washed with 2 M HCl (save the aqueous phase). 4 M NaOH wasadded to this aqueous phase until pH = 7-8 (cloudy solution), and this solution was extracted with diethyl ether. Finalorganic phase was dried over Na2SO4, and diethyl ether was removed in vacuo to afford the desired 1-(4-vinylbenzyl)-1Himidazole(S5) (6.55 g, 71percent yield) |
[ 56643-85-7 ]
4-Imidazol-1-ylmethylphenylamine
Similarity: 0.90
[ 179873-45-1 ]
N-Methyl-4-(1-imidazolyl)benzylamine
Similarity: 0.87
[ 886457-65-4 ]
(4-(1H-Imidazol-1-yl)phenyl)methanamine hydrochloride
Similarity: 0.83
[ 78712-43-3 ]
(E)-3-(4-((1H-Imidazol-1-yl)methyl)phenyl)acrylic acid hydrochloride
Similarity: 0.78
[ 4630-95-9 ]
3-(Diphenylmethylene)-1,1-diethyl-2-methylpyrrolidin-1-ium bromide
Similarity: 0.52
[ 56643-85-7 ]
4-Imidazol-1-ylmethylphenylamine
Similarity: 0.90
[ 179873-45-1 ]
N-Methyl-4-(1-imidazolyl)benzylamine
Similarity: 0.87
[ 886457-65-4 ]
(4-(1H-Imidazol-1-yl)phenyl)methanamine hydrochloride
Similarity: 0.83